Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Androgen Resistant Prostatic Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 0 results

Large-scale testing (Phase 3)Study completedNCT00838201
What this trial is testing

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Who this might be right for
CancerCarcinomaCastrate-Resistant Prostate Cancer+2 more
Amgen 384
Testing effectiveness (Phase 2)UnknownNCT04033432
What this trial is testing

SEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaCastration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents+7 more
Northwestern University 14
Testing effectiveness (Phase 2)Study completedNCT02286921
What this trial is testing

Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance

Who this might be right for
Castration Resistant Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 222
Testing effectiveness (Phase 2)Study completedNCT01090765
What this trial is testing

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

Who this might be right for
Prostate CancerMetastatic Castrate Resistant Prostate Cancer
National Cancer Institute (NCI) 21